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Abstract
The sequencing of the complete human genome led to a before and after in medicine and, 
specifically, in oncological treatments. Nowadays, we are getting closer to what we call 
personalized medicine, where it is necessary to know the individual biochemical mechanisms of 
each patient. The future predicts a precision medicine based on markers of toxicity and 
pharmacogenomics.
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Introduction
In the 60s, Yanase indicated for the first time the fact that different patients presented a 
different biochemistry, specifically in their response to anesthesia (1). However, it was not 
until 2003, with the complete sequencing of the human genome that a series of changes 
occurred in the approach to diseases based on genomics (2). The HapMap project, a catalog 
of common genetic variants of human DNA and of free access, was the next step (3). In turn, 
it was quickly overshadowed by the current project 1000 Genomes of the IGSR where we 
can find not only variants in human DNA, but other information such as its frequencies and 
correlations in samples of populations from different parts of the world (4).
Biomarkers, Pharmacogenomics and Precision Medicine
Currently, the use of biomarkers, pharmacogenomics and even the use of precision medicine 
seems even necessary in practically any pathology to obtain effective results in their 
treatment. Understanding that the response to medications is an individual response that 
depends on genetic and environmental factors, in addition to the interaction between them, is 
crucial nowadays to understand both the development of the disease and, mainly, its 
response to treatment (5).
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However, before the complete sequencing of the genome, Jennings already conducted 
studies to show that the differences found in the metabolism of anticonvulsants were due to a 
specific polymorphism (6). Other studies, also in the 1980s, studied the differences that 
patients presented in the metabolism of S conjugates of cysteine, related to the metabolism 
of many drugs, showing differences in the percentage of metabolites excreted between 
individuals (7). These differences were related to an autosomal recessive inheritance, 
although environmental factors could not be ruled out (8). However, T. J. Pallasch in his 
1988 review, where he treated the different factors that could affect the metabolism of drugs 
(9), related these differences observed among patients with factors such as sex, body weight 
or age (factors that we now know can affect genetic through epigenetic processes). Other 
studies focused on adverse drug reactions due to hereditary differences in methylating 
enzymes (10).
The first study in which it was applied directly in carcinogenesis process was from 
Vetticaden (1989). In this study, polymorphism directly associated with cytochrome P- 450 
variants, involved in drug metabolism was analyzed (11). The conclusion was that certain 
variants are related to a higher incidence of cancer, mainly lung cancer (12). But it was not 
until 2003, after the complete sequencing of the human genome when a pharmacogenomics 
application study was conducted in the treatment of cancer with 6-MP, which indicated a 
genetic deficiency of autosomal recessive inheritance in the activity of the thiopurine S- 
methyltransferase that made them more susceptible to drug toxicity (13).
Personalized Medicine in Oncology: past and future
Thanks to these early studies, patients now have access to important advances in the 
optimization of pharmacological treatment depending on the metabolic characteristics of the 
individual or the genetic characteristics of the tumor. Some examples of this in clinical 
practice are the study of the genotype of TPMT, ITPA, ABCC4 and ABCB1 related to the 
toxicity to mercaptopurine (14), analysis of genetic variants in the promoter region of the 
thymidylate synthase gene and its relationship with the response to treatment with 5-
Fluoracil (15) or previous study of polymorphisms of the UDP-glucuronosyl transferase 1A1 
gene in the treatment with inhibitors of EGFR receptors (16), among other examples.
Therefore, nowadays before performing a treatment with chemotherapy, it is necessary to 
study the genotype of the patient, so that the study of specific genotypes helps the clinician 
to make therapeutic decisions. For example, we know that mutations in the KRAS gene 
produce a low response to panitumumab or cetuximab in patients with colon cancer that 
patients suffering from lung cancer with mutations in the EGFR gene respond efficiently to 
treatment with Tarceva, among many others. An exhaustive study on this was carried out by 
Ong in 2012 (17). The latest example is FDA’s approval in 2018 of larotrectinib, indicated 
for any solid tumor with gene fusion of the receptor tyrosine kinase (NTRK) without known 
resistance mutation (18).
However, in the pharmacological response several genes usually intervene, so that more 
studies are needed in order to identify a greater number of regulatory genes for response to 
drugs and their interactions. This is being carried out successfully thanks to the development 
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of bioinformatics and microarray technology, mainly in acute leukemia, B-cell lymphomas 
or breast cancer (19).
Conclusion
The personalization of oncological treatments thanks to pharmacogenetics analysis will 
continue to improve. It will increase the number of studies and clinical trials that relate the 
genetics of the individual and the tumor with the response to treatment and, with it, the 
number of clinical guidelines that use this information.
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ABCB1 ATP-binding cassette bus-family B member 1
ABBC4 ATP-binding cassette sub-family C member 4
EGFR epidermal growth factor receptor
IGSR International Genome Sample Resource
ITPA inosine triphosphate pyrophosphatase
NTRK neurotrophic receptor tyrosine kinase
TPMT thiopurine S-methyltransferase
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